Diagnóstico, tratamiento y seguimiento | 24 SEP 18

Linfoma no Hodgkin

Los principios del diagnóstico y tratamiento que son especialmente importantes para los no especialistas, que pueden asistir a pacientes con linfoma no Hodgkin
Autor/a: Al-Naeeb AB, Ajithkumar T, Behan S et al BMJ 2018; 362:k3204
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1 Swerdlow SH, Campo E, Pileri SA, etal . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375-90. 10.1182/blood-2016-01-643569 26980727

2 Cancer Research UK (CRUK). Non-Hodgkin lymphoma statistics. www.cancerresearchuk. org/health-professional/cancer-statistics/statistics-by-cancer-type/non-hodgkin-lymphoma.

3 Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684-92. 10.1038/bjc.2011.450 22045184

4 Smith A, Crouch S, Lax S, etal . Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer 2015;112:1575-84. 10.1038/bjc.2015.94 25867256

5 International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2013. http://globocan.iarc.fr.

6 Müller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005;84:1-12.

7 Shaffer AL3rd, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012;30:565-610. 10.1146/annurev-immunol-020711-075027 22224767

8 Parkin DM. 11. Cancers attributable to infection in the UK in 2010. Br J Cancer 2011;105(Suppl 2):S49-56. 10.1038/bjc.2011.484 22158321

9 Morton LM, Slager SL, Cerhan JR, etal . Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014;2014:130-44.

10 Brown KF, Rumgay H, Dunlop C, etal . The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer 2018;118:1130-41. 10.1038/s41416-018-0029-6 29567982

11 Gurney KA, Cartwright RA. Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales. Hematol J 2002;3:95-104.

12 Chaganti S, Illidge T, Barrington S, etal. British Committee for Standards in Haematology. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol 2016;174:43-56. 10.1111/bjh.14136 27196701

13 Lister TA, Crowther D, Sutcliffe SB, etal . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6. 10.1200/JCO.1989.7.11.1630 2809679

14 Sehn LH, Berry B, Chhanabhai M, etal . The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-61.

10.1182/blood-2006-08-038257 17105812

15 National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NICE guideline NG12). Chapter 1: Recommendations organised by site of cancer. 2015. www.nice.org.uk/guidance/ng12/chapter/1-Recommendations-organised-by-siteof-cancer.

16 Coiffier B, Lepage E, Briere J, etal . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42. 10.1056/NEJMoa011795 11807147

17 Pfreundschuh M, Trümper L, Osterborg A, etal. MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.

18 Cunningham D, Hawkes EA, Jack A, etal . Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817-26. 10.1016/S0140-6736(13)60313-X 23615461

19 Chiappella A, Martelli M, Angelucci E, etal . Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol 2017;18:1076-88.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024